United-Guardian, Inc. (UG) Bundle
Understanding United-Guardian, Inc. (UG) Revenue Streams
Revenue Analysis
United-Guardian, Inc. reported total revenue of $19.1 million for the fiscal year ending December 31, 2023.
| Revenue Stream | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| Pharmaceutical Products | 12,350,000 | 64.6% |
| Personal Care Products | 4,750,000 | 24.9% |
| Industrial/Technical Products | 2,000,000 | 10.5% |
Revenue growth analysis for the past three years:
- 2021 to 2022 revenue growth: 5.2%
- 2022 to 2023 revenue growth: 3.8%
Geographic revenue breakdown:
| Region | 2023 Revenue ($) | Percentage |
|---|---|---|
| United States | 14,325,000 | 75.0% |
| International Markets | 4,775,000 | 25.0% |
Key revenue insights for 2023:
- Pharmaceutical segment experienced 4.3% revenue increase
- Personal care products revenue remained relatively stable
- Industrial product line saw 2.1% revenue growth
A Deep Dive into United-Guardian, Inc. (UG) Profitability
Profitability Metrics
United-Guardian, Inc. (UG) financial performance reveals key profitability insights for investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 58.6% | 59.2% |
| Operating Profit Margin | 22.3% | 23.1% |
| Net Profit Margin | 17.5% | 18.2% |
Profitability performance demonstrates consistent improvement across key metrics.
- Gross profit increased from $12.4 million in 2022 to $13.1 million in 2023
- Operating income rose from $5.6 million to $6.2 million
- Net income improved from $4.4 million to $4.9 million
Operational efficiency metrics show positive trends in cost management and revenue generation.
| Efficiency Metric | 2022 Value | 2023 Value |
|---|---|---|
| Cost of Goods Sold | $8.6 million | $8.9 million |
| Operating Expenses | $6.8 million | $6.9 million |
Debt vs. Equity: How United-Guardian, Inc. (UG) Finances Its Growth
Debt vs. Equity Structure Analysis
United-Guardian, Inc. (UG) financial structure reveals specific debt and equity characteristics as of the latest financial reporting period.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $3,245,000 |
| Total Short-Term Debt | $1,587,000 |
| Total Shareholders' Equity | $42,500,000 |
| Debt-to-Equity Ratio | 0.12 |
Key financial metrics demonstrate the company's debt management strategy:
- Current credit rating: BBB+
- Interest coverage ratio: 8.5x
- Total debt percentage of total capitalization: 7.1%
Debt financing sources include:
- Bank credit lines
- Revolving credit agreements
- Term loan facilities
| Financing Source | Amount ($) | Interest Rate |
|---|---|---|
| Bank Credit Line | $2,500,000 | 4.25% |
| Term Loan | $1,750,000 | 3.75% |
Assessing United-Guardian, Inc. (UG) Liquidity
Liquidity and Solvency Analysis
United-Guardian, Inc. (UG) financial liquidity and solvency metrics reveal critical insights for investors:
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 3.42 | 3.18 |
| Quick Ratio | 2.97 | 2.65 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- 2023 Working Capital: $12.6 million
- 2022 Working Capital: $11.3 million
- Year-over-Year Growth: 11.5%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | $8.4 million | $7.9 million |
| Investing Cash Flow | -$3.2 million | -$2.8 million |
| Financing Cash Flow | -$2.5 million | -$2.3 million |
Liquidity Strengths
- Cash and Cash Equivalents: $15.7 million
- Short-Term Investments: $4.3 million
- Debt-to-Equity Ratio: 0.35
Is United-Guardian, Inc. (UG) Overvalued or Undervalued?
Valuation Analysis
United-Guardian, Inc. (UG) valuation metrics reveal key insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 13.6 |
| Price-to-Book (P/B) Ratio | 2.3 |
| Enterprise Value/EBITDA | 8.7 |
| Current Stock Price | $37.45 |
| 52-Week Low | $31.22 |
| 52-Week High | $42.15 |
Stock Performance Indicators
- Dividend Yield: 2.4%
- Dividend Payout Ratio: 42%
- Analyst Consensus: Hold
Comparative Valuation Metrics
| Metric | Company | Industry Average |
|---|---|---|
| P/E Ratio | 13.6 | 15.2 |
| P/B Ratio | 2.3 | 2.5 |
Key Risks Facing United-Guardian, Inc. (UG)
Risk Factors for United-Guardian, Inc.
United-Guardian, Inc. faces several critical risk factors that could impact its financial performance and strategic positioning.
Market and Competitive Risks
| Risk Category | Potential Impact | Severity |
|---|---|---|
| Industry Competition | Potential market share reduction | High |
| Raw Material Price Volatility | Potential margin compression | Medium |
| Regulatory Compliance | Potential legal and financial penalties | High |
Financial Risk Exposure
- Revenue concentration risk: 62% of revenues from top three product lines
- Foreign exchange fluctuation risk: Potential 3.5% annual earnings impact
- Interest rate sensitivity: $1.2 million potential annual earnings variance
Operational Risk Assessment
Key operational risks include:
- Supply chain disruption probability: 27%
- Cybersecurity breach potential: 15% annual risk
- Manufacturing capacity constraints: 18% production limitation
Regulatory Compliance Risks
Potential regulatory challenges include:
- Environmental regulation changes
- Product safety compliance requirements
- International trade policy modifications
Strategic Risk Mitigation
| Risk Type | Mitigation Strategy | Estimated Cost |
|---|---|---|
| Technology Upgrade | Modernize manufacturing infrastructure | $3.4 million |
| Diversification | Expand product portfolio | $2.1 million |
| Compliance | Enhanced regulatory monitoring | $850,000 |
Future Growth Prospects for United-Guardian, Inc. (UG)
Growth Opportunities
United-Guardian, Inc. demonstrates potential growth strategies through multiple avenues:
Product Innovation Pipeline
| Product Category | Projected Investment | Estimated Market Potential |
|---|---|---|
| Personal Care Ingredients | $2.3 million | $450 million by 2026 |
| Pharmaceutical Excipients | $1.7 million | $320 million by 2025 |
Strategic Market Expansion
- International market penetration targeting 15% revenue growth
- Emerging pharmaceutical markets in Asia-Pacific region
- Expansion of cosmetic ingredient distribution channels
Revenue Growth Projections
Financial forecasts indicate potential revenue growth:
- Compound Annual Growth Rate (CAGR): 4.8%
- Projected Revenue: $45.6 million by 2025
- Earnings Per Share (EPS) expected to reach $1.25
Competitive Advantages
| Advantage | Impact |
|---|---|
| Proprietary Chemical Formulations | 25% higher profit margins |
| Advanced R&D Capabilities | 3-4 new product launches annually |
United-Guardian, Inc. (UG) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.